A Long-term Follow up Study of EXG102-031 in Participants With wAMD
ConditionWet Age-related Macular Degeneration
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorGuangzhou Jiayin Biotech Ltd
About this trial
This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.
Eligibility criteria
Qualifiers
Previously received treatment with EXG102-031 in the study (EXG102-031-111);
Paticipantes are informed consent and willingness to follow protocol procedures.
Disqualifiers
None
Trial design
Treatments tested in this trial
- No intervention, only for observational studies
Treatment groups
No treatment groups listed
Sponsors and collaborators
Guangzhou Jiayin Biotech Ltd
Lead sponsor
Peking University People's Hospital
Collaborator
Source ClinicalTrials.gov